post #90 answers the question as asked. The question underneath it is different.
Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute.
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
post #90 answers the question as asked. The question underneath it is different.
Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's core but not central.
Coming back to post #92, because the follow-up matters more than the original answer.
Not a rules-free zone: the guidelines still apply. No phones, no Telegram, no endorsements of other communities. Just a relaxed bar for how directly the topic needs to relate.
Community norms: if you want to discuss how the community should work (not moderation decisions, which go in Meta) the Lounge is a place for that casual discussion.
Lower-stakes conversation that does not belong in the technical categories. Still civil, still sourced when a claim is made, but the bar for relevance is lower.
This follows post #94 rather than contradicting it.
Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not.
Personal stories: if you want to talk about what led you to this compound, your journey, or how the change has affected your life, the Lounge is the place for that.
Humour: light, relevant humour is welcome. Cruel humour targeting individuals or groups is not.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
This follows post #100 rather than contradicting it.
Community norms: if you want to discuss how the community should work (not moderation decisions, which go in Meta) the Lounge is a place for that casual discussion.
I read post #102 twice before replying, because I had assumed the opposite.
Lower-stakes conversation that does not belong in the technical categories. Still civil, still sourced when a claim is made, but the bar for relevance is lower.
Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute.
On post #102 — agreed on the reasoning, with one qualification.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Picking up post #104: that is the part I would want checked first.
Personal stories: if you want to talk about what led you to this compound, your journey, or how the change has affected your life, the Lounge is the place for that.
Humour: light, relevant humour is welcome. Cruel humour targeting individuals or groups is not.
post #108 is right about the mechanism and I think understates the practical bit.
Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not.
Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's core but not central.
Not a rules-free zone: the guidelines still apply. No phones, no Telegram, no endorsements of other communities. Just a relaxed bar for how directly the topic needs to relate.
post #113 answers the question as asked. The question underneath it is different.
Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute.
Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's core but not central.
Picking up post #117: that is the part I would want checked first.
Personal stories: if you want to talk about what led you to this compound, your journey, or how the change has affected your life, the Lounge is the place for that.